MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA.
Vaccine. 2013 Jan 30;31(6):857-60. doi: 10.1016/j.vaccine.2012.12.028. Epub 2012 Dec 20.
Intranasal live attenuated influenza vaccine (LAIV) has potential for self-administration (SA) by adults and adolescents, which could save time and cost in mass vaccination settings. Participants in a study of LAIV in adults (n=4561) selected either SA or health care provider (HCP) administration and were followed for febrile illness during the influenza season. More LAIV recipients chose SA-LAIV (72%) than HCP-LAIV (28%). Overall, 97% of SA-LAIV and 98% of HCP-LAIV recipients had no problems with vaccine administration. Four of 13 study sites enrolled more than 50 subjects in both cohorts. Overall and for these 4 sites, illness incidence was similar with SA-LAIV and HCP-LAIV. Solicited reactogenicity events and adverse events through 7 days post vaccination were comparable for SA-LAIV and HCP-LAIV recipients; both groups exhibited increased runny nose, sore throat, and cough relative to placebo recipients. SA-LAIV and HCP-LAIV appeared similarly effective against influenza-like illness and had comparable safety profiles.
鼻内接种的减毒活流感疫苗（LAIV）具有供成人和青少年自我接种（SA）的潜力，这在大规模疫苗接种环境中可以节省时间和成本。一项针对成人 LAIV 的研究中，参与者（n=4561）选择 SA 或医护人员（HCP）接种，并在流感季节期间跟踪发热疾病情况。选择 SA-LAIV 的 LAIV 接种者（72%）多于选择 HCP-LAIV 的接种者（28%）。总体而言，97%的 SA-LAIV 和 98%的 HCP-LAIV 接种者在疫苗接种过程中没有问题。有 13 个研究地点中的 4 个在两个队列中都招募了超过 50 名受试者。总体而言，对于这 4 个地点，SA-LAIV 和 HCP-LAIV 的疾病发病率相似。SA-LAIV 和 HCP-LAIV 接种者在接种后 7 天内出现的不良反应事件相似；与安慰剂组相比，两组都出现了流鼻涕、喉咙痛和咳嗽增多的情况。SA-LAIV 和 HCP-LAIV 对流感样疾病的疗效相似，安全性特征相似。
